Previous close | 2.2500 |
Open | 2.2500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 30.00 |
Expiry date | 2024-11-15 |
Day's range | 2.2500 - 2.2500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Celldex Therapeutics ( NASDAQ:CLDX ) First Quarter 2024 Results Key Financial Results Net loss: US$32.8m (loss widened...
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 -- Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study -- Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 - HAMPTON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeut